- Home
- PHAT
as 10-29-2025 4:00pm EST
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 769.0M | IPO Year: | 2019 |
| Target Price: | $16.40 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.71 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.21 - $19.50 | Next Earning Date: | 10-30-2025 |
| Revenue: | $114,039,000 | Revenue Growth: | 1049.82% |
| Revenue Growth (this year): | 213.65% | Revenue Growth (next year): | 91.41% |
Stock Insider Trading Activity of Phathom Pharmaceuticals Inc. (PHAT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Breedlove Robert Charles | PHAT | Principal Accounting Officer | Sep 5 '25 | Sell | $12.09 | 461 | $5,573.49 | 47,931 |
Latest Phathom Pharmaceuticals Inc. News
PHAT Breaking Stock News: Dive into PHAT Ticker-Specific Updates for Smart Investing
MT Newswires
23 days ago
Phathom Pharmaceuticals Names Sanjeev Narula Finance, Business Chief
GlobeNewswire
24 days ago
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
Simply Wall St.
a month ago
Phathom Pharmaceuticals (NASDAQ:PHAT) adds US$64m to market cap in the past 7 days, though investors from five years ago are still down 67%
Zacks
2 months ago
Wall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?
GlobeNewswire
4 months ago
Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
4 months ago
Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary
MT Newswires
4 months ago
Phathom Pharmaceuticals' Heartburn Drug Receives Regulatory Exclusivity in FDA Orange Book Update
GlobeNewswire
4 months ago
Phathom Pharmaceuticals Announces FDA Correction to Orange Book Listing, Confirming 10 Years of Regulatory Exclusivity for VOQUEZNA® (vonoprazan) Tablets Through May 3, 2032
Compare PHAT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PHAT Phathom Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.